SCHEDULE: Farallon Capital Reports 8.1% Stake in Assembly Biosciences

Farallon Capital Management and affiliated entities report beneficial ownership of 1,604,590 shares, representing 8.1% of Assembly Biosciences' common stock.

Summary

• Farallon Capital Management, L.L.C. and several affiliated entities (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating their beneficial ownership of Assembly Biosciences, Inc. common stock.
• As of June 30, 2026, the Reporting Persons collectively beneficially own 1,604,590 shares of common stock, representing 8.1% of the class.
• The shares are held through various investment partnerships managed by Farallon Capital Management, L.L.C.
• The filing also notes the ownership of 510,205 Class A Warrants and 510,205 Class B Warrants, which are subject to a Beneficial Ownership Limitation of 4.99%.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on beneficial ownership changes and does not contain operational or financial performance updates.

Positives

• Farallon Capital Management, a significant investment firm, has taken a notable stake in Assembly Biosciences, potentially signaling confidence in the company's future prospects.
• The reporting of this stake is a standard disclosure, providing transparency to the market regarding significant beneficial ownership.

Negatives

• The filing does not provide any operational or financial performance data for Assembly Biosciences, limiting insights into the company's current health.
• The Beneficial Ownership Limitation of 4.99% on warrants may restrict future exercise and potential increase in ownership for Farallon.

Risks

• The Class B Warrants are not exercisable until November 15, 2026, introducing a time-based risk for potential future share acquisition.
• The Beneficial Ownership Limitation of 4.99% could prevent the full exercise of warrants if the company's outstanding shares increase significantly.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Assembly Biosciences' future performance. It primarily details current beneficial ownership and warrant holdings.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by institutional investors, as reported in Schedule 13G filings, often precede or coincide with periods of strategic review or operational changes within a company. The biotech sector, in particular, sees active participation from specialized investment firms like Farallon Capital.

Stakeholder Impact

• Shareholders: Increased institutional ownership by a prominent firm like Farallon Capital may be viewed positively, potentially signaling increased investor interest or confidence.
• Management: The significant stake may influence board dynamics or strategic decisions, depending on Farallon's investment strategy.
• Potential Investors: The filing provides transparency on a major shareholder, aiding in investment analysis.

Next Steps

• Farallon Capital Management will continue to monitor its investment in Assembly Biosciences.
• Future amendments to this Schedule 13G will be filed if beneficial ownership changes significantly.

Key Dates

Keywords

Assembly Biosciences, Farallon Capital Management, Schedule 13G, Beneficial Ownership, Warrants, Investment Partnerships, Common Stock